No Data
Subdued Growth No Barrier To Hainan Huluwa Pharmaceutical Group Co., Ltd. (SHSE:605199) With Shares Advancing 43%
In November, the frenzy of "mystical stock trading" is in full swing, with the strongest bull stock experiencing 15 daily limit-ups in 20 days, trading Eastern related stocks, zodiac Snake related stocks, numerical series, etc...
Attention economy.
Hainan Huluwa Pharmaceutical Group (605199.SH): There are no significant matters that should have been disclosed but have not been disclosed.
On November 29, Glonghui reported that hainan huluwa pharmaceutical group (605199.SH) announced that its stocks have experienced a continuous daily price limit rise from November 26, 2024, to November 29, 2024, with a cumulative increase of 46.40%. The turnover ratio over the last four trading days has reached 19.83%. The company specifically reminds investors to be aware of risks in the secondary market, make rational decisions, and invest cautiously. After the company's self-inspection and written verification with its controlling shareholder and actual controller, it is confirmed that as of the date of this announcement, there are no significant matters that should be disclosed but have not been disclosed.
hainan huluwa pharmaceutical group (605199.SH): Zhongjia Rui has cumulatively reduced their shareholding by 1.33%.
Hainan Huluwa Pharmaceutical Group (605199.SH) announced on November 27th that on November 26, 2024, the company received a notice from Zhongjiarui regarding the completion of the implementation of the shareholding reduction plan. Zhongjiarui reduced a total of 5,341,050 shares between November 25, 2024 and November 26, 2024, accounting for 1.33% of the company's total share capital.
Here's Why Hainan Huluwa Pharmaceutical Group (SHSE:605199) Has A Meaningful Debt Burden
Hainan Huluwa Pharmaceutical Group (605199.SH): received government subsidies of 10.6863 million yuan
Hainan Huluwa Pharmaceutical Group (605199.SH) announced that the company and its subsidiaries received a total of RMB 10.6863 million in government grants related to revenue from May 31, 2024, to the date of this announcement, unaudited, accounting for 10.03% of the net income attributable to the parent company owner in 2023.
Hainan Huluwa Pharmaceutical Group Co., Ltd. (SHSE:605199) Shares May Have Slumped 25% But Getting In Cheap Is Still UnlikelyNo Data
No Data
